December 3, 2021
Shionogi said on December 2 that it has received Taiwan regulatory approval for Symproic (naldemedine) for the indication of opioid-induced constipation (OIC) in adult patients. Symproic was launched in Japan and the US in June and October 2017, respectively. In...read more